|
BioCentury
@
BioCentury
Redwood City, CA
|
|
The leading voice for decision makers throughout the global healthcare ecosystem.
|
|
|
27.800
Tweetovi
|
876
Pratim
|
9.742
Osobe koje vas prate
|
| Tweetovi |
|
BioCentury
@BioCentury
|
11 h |
|
|
||
|
|
||
|
BioCentury
@BioCentury
|
12 h |
|
|
||
|
BioCentury
@BioCentury
|
12 h |
|
Initial efficacy data suggest CAR NK cells could compete with CAR Ts in blood cancers. buff.ly/2GXbr7J
|
||
|
|
||
|
BioCentury
@BioCentury
|
13 h |
|
After Merck spins out slower-growing businesses to focus on innovation, the company will need recent and future deals to yield fruit in order to balance its reliance on Keytruda for growth $MRK buff.ly/31t3QqR pic.twitter.com/Tk8AKxjq6O
|
||
|
|
||
|
BioCentury
@BioCentury
|
14 h |
|
Trump endorses Grassley-Wyden drug pricing bill buff.ly/2ubuGaR
|
||
|
|
||
|
BioCentury
@BioCentury
|
15 h |
|
A big win for @Biogen on #Tecfidera IPR, adding nearly $9B in market cap. With overhang lifted, investors now turn full attention to #Alzheimers candidate #aducanumab $BIIB buff.ly/2SpCC0h
|
||
|
|
||
|
BioCentury
@BioCentury
|
15 h |
|
FDA's Richard Pazdur supports expanded access for unapproved uses of approved drugs buff.ly/2GXUU3h pic.twitter.com/fdIfJPOQQy
|
||
|
|
||
|
BioCentury
@BioCentury
|
15 h |
|
EMA hopes to lower barriers to use of real-world data in regulatory decision making by creating a centralized system for integrating RWD across Europe. buff.ly/2GUgoho pic.twitter.com/uEML8Qo1Qb
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
.@a16z's Vijay Pande tells @BioCentury's @_Ktktktktk the firm is investing new $750M fund in “weak AI” -- speeding and scaling up tasks humans can do -- while tech that could enable “strong AI,” which does things humans can’t do, matures. biocentury.com/article/304379
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Josh Berlin
@BioPharmaJosh
|
21 h |
|
3/ Clinical trial delays in China could have a wide impact on the global biopharma industry. More analysis here from my colleague @li_hongjiang -> biocentury.com/article/304370 #2019nCOV #coronavirus pic.twitter.com/ZOM6XZAtP6
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Josh Berlin
@BioPharmaJosh
|
5. velj |
|
2/ICYMI: Draft report from @WHO R&D Blueprint Clinical Trials expert group singles out Gilead's remdesivir as most promising candidate for #2019nCoV (free analysis) biocentury.com/article/304374 via @BioCentury $GILD #coronavirus pic.twitter.com/zxGO4I0O2l
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Josh Berlin
@BioPharmaJosh
|
4. velj |
|
We have created a free webpage that collects @BioCentury analysis of the #coronavirus outbreak. Please bookmark this page. It will be updated frequently. The most recent story tracks clinical trials. biocentury.com/coronavirus #2019nCoV pic.twitter.com/hCSzCPQit2
|
||
|
|
||
|
BioCentury
@BioCentury
|
5. velj |
|
Andreessen Horowitz GPs see opportunities for "weak AI," diagnostics and synthetic biology with $750M Bio Fund III @a16z buff.ly/2Scgoyo
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Kiran Mazumdar Shaw
@kiranshaw
|
29. sij |
|
BioCentury - DARPA-funded AbCellera to develop mAbs to treat coronavirus outbreak - this is what India ought to do for which we need a genomic repository of viruses @DBTIndia biocentury.com/bc-extra/compa…
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Adam Gordon
@asg3
|
4. velj |
|
Read more #coronavirus analysis from @biocentury in our free collection.
biocentury.com/coronavirus twitter.com/krebs_matt/sta…
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
4. velj |
|
Delays hit clinical trials in China. @BioCentury's @li_hongjiang speaks with Foundation's Dan Zhang and HitGen's Jin Li on #2019nCoV's impact on clinical research. biocentury.com/article/304370 For open access to all of BioCentury's #Coronavirus coverage see: biocentury.com/coronavirus pic.twitter.com/gDHRLigbA9
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
4. velj |
|
$GILD to begin enrolling patients mid-Feb in 2 trials of #remdesivir to treat #2019nCoV acute respiratory disease via @BioCentury's @LaboratoryLiz biocentury.com/article/304364 pic.twitter.com/dLlAnArZS7
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
.@WHO draft report: $GILD's remdesivir most "promising" candidate to treat #2019nCoV, planning for trial under way. $GILD says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via @BioCentury biocentury.com/article/304374
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
CEO O'Day: $GILD has sense of "urgency" for M&A, seeking “transformative" deals a la $GLPG, as well as small- to medium-sized bolt-on takeouts. Co also working “night and day” to ramp up manufacturing for #2019nCoV therapy via @BioCentury's @LaboratoryLiz biocentury.com/article/304375
|
||
|
|
||
| BioCentury proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
5. velj |
|
At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the #2019nCoV outbreak. An analysis of cos most active in the region finds Roche could be most affected. via @BioCentury biocentury.com/article/304378 pic.twitter.com/UhUM5dh5VE
|
||
|
|
||